Renal cancer treatment with low levels of mixed chimerism induced by nonmyeloablative regimen using cyclophosphamide in mice

Masahiko Harano, Masatoshi Eto, Toshiro Iwai, Katsunori Tatsugami, Keijiro Kiyoshima, Yoriyuki Kamiryo, Masazumi Tsuneyoshi, Yasunobu Yoshikai, Seiji Naito

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Recently, much attention has been paid to nonmyeloablative allogeneic stem cell transplantation for the treatment of metastatic renal cancer. Mature donor T cells cause graft-versus-host disease (GVHD) although they are also the main mediators of the beneficial graft-versus-tumor activity associated with this treatment. Hence, the segregation of the graft-versus-tumor activity from GVHD is an important challenge in managing the clinical course of treatment. We previously reported a series of studies regarding the allograft tolerance induced by allogeneic spleen cells (with bone marrow cells) and cyclophosphamide in mice. Here, we show a modified cyclophosphamide-induced tolerance system for the treatment of murine renal cell carcinoma, RENCA, by shifting the equal balance between graft-versus-host and host-versus-graft reactions toward graft-versus-host reaction with donor lymphocyte infusion. Our results clearly show the antitumor activity against RENCA with only low levels of mixed chimerism in the periphery and the in vivo and in vitro acquired immunity against RENCA even when mixed chimerism is almost undetectable. Because the withdrawal of mixed chimerism reduces the risk of GVHD, the antitumor activity is thus sequentially segregated from the initial GVHD in our model. We believe that this is the first unique model system of nonmyeloablative allogeneic hemopoietic cell transplantation to ever be reported for the treatment of renal cancer.

Original languageEnglish
Pages (from-to)10032-10040
Number of pages9
JournalCancer Research
Volume65
Issue number21
DOIs
Publication statusPublished - Nov 1 2005

Fingerprint

Chimerism
Kidney Neoplasms
Cyclophosphamide
Graft vs Host Disease
Transplants
Transplantation Tolerance
Therapeutics
Cell Transplantation
Stem Cell Transplantation
Adaptive Immunity
Renal Cell Carcinoma
Bone Marrow Cells
Neoplasms
Spleen
Lymphocytes
T-Lymphocytes

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Renal cancer treatment with low levels of mixed chimerism induced by nonmyeloablative regimen using cyclophosphamide in mice. / Harano, Masahiko; Eto, Masatoshi; Iwai, Toshiro; Tatsugami, Katsunori; Kiyoshima, Keijiro; Kamiryo, Yoriyuki; Tsuneyoshi, Masazumi; Yoshikai, Yasunobu; Naito, Seiji.

In: Cancer Research, Vol. 65, No. 21, 01.11.2005, p. 10032-10040.

Research output: Contribution to journalArticle

Harano, Masahiko ; Eto, Masatoshi ; Iwai, Toshiro ; Tatsugami, Katsunori ; Kiyoshima, Keijiro ; Kamiryo, Yoriyuki ; Tsuneyoshi, Masazumi ; Yoshikai, Yasunobu ; Naito, Seiji. / Renal cancer treatment with low levels of mixed chimerism induced by nonmyeloablative regimen using cyclophosphamide in mice. In: Cancer Research. 2005 ; Vol. 65, No. 21. pp. 10032-10040.
@article{deb8ee8ba1ce4d77970a076cb823b8f9,
title = "Renal cancer treatment with low levels of mixed chimerism induced by nonmyeloablative regimen using cyclophosphamide in mice",
abstract = "Recently, much attention has been paid to nonmyeloablative allogeneic stem cell transplantation for the treatment of metastatic renal cancer. Mature donor T cells cause graft-versus-host disease (GVHD) although they are also the main mediators of the beneficial graft-versus-tumor activity associated with this treatment. Hence, the segregation of the graft-versus-tumor activity from GVHD is an important challenge in managing the clinical course of treatment. We previously reported a series of studies regarding the allograft tolerance induced by allogeneic spleen cells (with bone marrow cells) and cyclophosphamide in mice. Here, we show a modified cyclophosphamide-induced tolerance system for the treatment of murine renal cell carcinoma, RENCA, by shifting the equal balance between graft-versus-host and host-versus-graft reactions toward graft-versus-host reaction with donor lymphocyte infusion. Our results clearly show the antitumor activity against RENCA with only low levels of mixed chimerism in the periphery and the in vivo and in vitro acquired immunity against RENCA even when mixed chimerism is almost undetectable. Because the withdrawal of mixed chimerism reduces the risk of GVHD, the antitumor activity is thus sequentially segregated from the initial GVHD in our model. We believe that this is the first unique model system of nonmyeloablative allogeneic hemopoietic cell transplantation to ever be reported for the treatment of renal cancer.",
author = "Masahiko Harano and Masatoshi Eto and Toshiro Iwai and Katsunori Tatsugami and Keijiro Kiyoshima and Yoriyuki Kamiryo and Masazumi Tsuneyoshi and Yasunobu Yoshikai and Seiji Naito",
year = "2005",
month = "11",
day = "1",
doi = "10.1158/0008-5472.CAN-05-0457",
language = "English",
volume = "65",
pages = "10032--10040",
journal = "Cancer Research",
issn = "0008-5472",
number = "21",

}

TY - JOUR

T1 - Renal cancer treatment with low levels of mixed chimerism induced by nonmyeloablative regimen using cyclophosphamide in mice

AU - Harano, Masahiko

AU - Eto, Masatoshi

AU - Iwai, Toshiro

AU - Tatsugami, Katsunori

AU - Kiyoshima, Keijiro

AU - Kamiryo, Yoriyuki

AU - Tsuneyoshi, Masazumi

AU - Yoshikai, Yasunobu

AU - Naito, Seiji

PY - 2005/11/1

Y1 - 2005/11/1

N2 - Recently, much attention has been paid to nonmyeloablative allogeneic stem cell transplantation for the treatment of metastatic renal cancer. Mature donor T cells cause graft-versus-host disease (GVHD) although they are also the main mediators of the beneficial graft-versus-tumor activity associated with this treatment. Hence, the segregation of the graft-versus-tumor activity from GVHD is an important challenge in managing the clinical course of treatment. We previously reported a series of studies regarding the allograft tolerance induced by allogeneic spleen cells (with bone marrow cells) and cyclophosphamide in mice. Here, we show a modified cyclophosphamide-induced tolerance system for the treatment of murine renal cell carcinoma, RENCA, by shifting the equal balance between graft-versus-host and host-versus-graft reactions toward graft-versus-host reaction with donor lymphocyte infusion. Our results clearly show the antitumor activity against RENCA with only low levels of mixed chimerism in the periphery and the in vivo and in vitro acquired immunity against RENCA even when mixed chimerism is almost undetectable. Because the withdrawal of mixed chimerism reduces the risk of GVHD, the antitumor activity is thus sequentially segregated from the initial GVHD in our model. We believe that this is the first unique model system of nonmyeloablative allogeneic hemopoietic cell transplantation to ever be reported for the treatment of renal cancer.

AB - Recently, much attention has been paid to nonmyeloablative allogeneic stem cell transplantation for the treatment of metastatic renal cancer. Mature donor T cells cause graft-versus-host disease (GVHD) although they are also the main mediators of the beneficial graft-versus-tumor activity associated with this treatment. Hence, the segregation of the graft-versus-tumor activity from GVHD is an important challenge in managing the clinical course of treatment. We previously reported a series of studies regarding the allograft tolerance induced by allogeneic spleen cells (with bone marrow cells) and cyclophosphamide in mice. Here, we show a modified cyclophosphamide-induced tolerance system for the treatment of murine renal cell carcinoma, RENCA, by shifting the equal balance between graft-versus-host and host-versus-graft reactions toward graft-versus-host reaction with donor lymphocyte infusion. Our results clearly show the antitumor activity against RENCA with only low levels of mixed chimerism in the periphery and the in vivo and in vitro acquired immunity against RENCA even when mixed chimerism is almost undetectable. Because the withdrawal of mixed chimerism reduces the risk of GVHD, the antitumor activity is thus sequentially segregated from the initial GVHD in our model. We believe that this is the first unique model system of nonmyeloablative allogeneic hemopoietic cell transplantation to ever be reported for the treatment of renal cancer.

UR - http://www.scopus.com/inward/record.url?scp=27544454955&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=27544454955&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-05-0457

DO - 10.1158/0008-5472.CAN-05-0457

M3 - Article

C2 - 16267029

AN - SCOPUS:27544454955

VL - 65

SP - 10032

EP - 10040

JO - Cancer Research

JF - Cancer Research

SN - 0008-5472

IS - 21

ER -